Amicus ended FY’22 with a growing topline and reassuring outlook from the management. The company seems well-prepared for pre-approval inspection and also seems optimistic about regulatory approval of ...

The market expects Amicus Therapeutics (FOLD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...